Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s disease ; volume:9 ; number:1 ; day:26 ; month:3 ; year:2019 ; pages:1-7 ; date:12.2019
Scientific reports ; 9, Heft 1 (26.3.2019), 1-7, 12.2019
- Klassifikation
-
Naturwissenschaften
- Urheber
-
Jasiecki, Jacek
Limon-Sztencel, Anna
Żuk, Monika
Chmara, Magdalena
Cysewski, Dominik
Limon, Janusz
Wasąg, Bartosz
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-41578-3
- URN
-
urn:nbn:de:101:1-2019041401115717196808
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jasiecki, Jacek
- Limon-Sztencel, Anna
- Żuk, Monika
- Chmara, Magdalena
- Cysewski, Dominik
- Limon, Janusz
- Wasąg, Bartosz
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Identifying genetic interactions associated with late-onset Alzheimer’s disease
Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease
Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups
Early and late-onset Alzheimer’s disease: What are the differences?
The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease
Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Identifying genetic interactions associated with late-onset Alzheimer’s disease
Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease
Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups
Early and late-onset Alzheimer’s disease: What are the differences?
The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease
Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Identifying genetic interactions associated with late-onset Alzheimer’s disease
Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease
Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups
Early and late-onset Alzheimer’s disease: What are the differences?
The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease